中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.023 seconds)

    NON-NATURAL GALANIN RECEPTOR LIGANDS
    2.
    发明申请
    NON-NATURAL GALANIN RECEPTOR LIGANDS 审中-公开
    非天然GALANIN受体配体

    公开(公告)号：WO2002096934A1

    公开(公告)日：2002-12-05

    申请号：PCT/SE2002/001002

    申请日：2002-05-24

    Applicant: KEMIA, INC. ,  LANGEL, Ülo ,  SAAR, Külliki ,  BARTFAI, Tamas

    Inventor： LANGEL, Ülo ,  SAAR, Külliki ,  BARTFAI, Tamas

    IPC: C07K5/06

    CPC classification number: C07K5/06078 ,  A61K38/00

    Abstract: Compounds which are non-natural galanin receptor ligands are disclosed. The ligands are of small size, have agonist or antagonist galanin activity and may cross the blood-brain barrier to displace galanin receptors. The ligands are useful as medicaments for treatment of convulsions (e.g. in epilepsy), diseases and disorders related to endocrinology (e.g., growth hormone, insulin or prolactin release), tumors expressing galanin receptors, feeding disorders pain, allodynia, psychiatric disorders such as depression (involving e.g., noradrenaline or serotonin), cognitive disorders (e.g. Alzeimer's disease), and the like.

    Abstract translation: 公开了非天然甘氨酸受体配体的化合物。 配体是小尺寸的，具有激动剂或拮抗剂甘丙肽活性，并且可以穿过血脑屏障来置换甘丙肽受体。 配体可用作治疗惊厥（例如癫痫），与内分泌学（例如生长激素，胰岛素或催乳素释放）相关的疾病和病症的药物，表达甘丙肽受体的肿瘤，进食障碍性疼痛，异常性疼痛，抑郁症等精神疾病 （例如，去甲肾上腺素或5-羟色胺），认知障碍（例如Alzeimer病）等。

    PEPTIDOMIMETIC GALANIN RECEPTOR MODULATORS
    3.
    发明申请
    PEPTIDOMIMETIC GALANIN RECEPTOR MODULATORS 审中-公开
    拟肽多糖体加强素受体调节剂

    公开(公告)号：WO2012009258A3

    公开(公告)日：2012-05-18

    申请号：PCT/US2011043522

    申请日：2011-07-11

    Applicant: ROBERTS EDWARD ,  BARTFAI TAMAS ,  LU XIAOYING ,  LIU TIANYU ,  SAGI VASUDEVA NAIDU

    Inventor： ROBERTS EDWARD ,  BARTFAI TAMAS ,  LU XIAOYING ,  LIU TIANYU ,  SAGI VASUDEVA NAIDU

    IPC: A01N43/42 ,  A61K31/47

    CPC classification number: C07D403/12 ,  C07C271/22 ,  C07D215/227 ,  C07D251/46 ,  C07D311/16 ,  C07D401/12 ,  C07D403/04 ,  C07D403/14 ,  C07D487/04 ,  C07K5/06026 ,  C07K5/06043 ,  C07K5/06069 ,  C07K5/06078 ,  C07K5/06113 ,  C07K5/06139 ,  C07K5/06147 ,  C07K5/06156 ,  C07K5/06165

    Abstract: Potent and effective modulators of galanin receptors such as Ga1R1 and Ga1R2 are provided. Methods of preparation and methods of use are further provided. The compounds of the invention may be effective for treatment of malconditions in human patients including epilepsy or seizure disorders, mood disorders including depression and anxiety spectrum disorders; drug addiction including addiction to alcohol or tobacco; autistic spectrum diseases and pervasive development disorders; Alzheimer's disease or other dementias; cognition disorders; cerebral or myocardial stroke; demyelinating diseases including multiple sclerosis, Guillain-Barre syndrome and Charcot-Marie-Tooth disease; neurodegenerative diseases including Parkinson's disease, Lou Gehrig's diseases, Huntington's disease, and HIV dementia; neurotrauma; diabetes, obesity, metabolic syndrome and feeding disorders; solid tumors and leukemia/lymphoma; pain; neuropathies; sleeping disorders and regulation; neuroprotection; and inflammation.

    Abstract translation: 提供了有效和有效的甘丙肽受体调节剂，如Ga1R1和Ga1R2。 还提供了制备方法和使用方法。 本发明化合物可用于治疗人类患者的病态，包括癫痫或癫痫发作，包括抑郁症和焦虑症的情绪障碍; 吸毒成瘾，包括酒精或烟草成瘾; 自闭症谱系疾病和普遍发展障碍; 阿尔茨海默氏病或​​其他痴呆症; 认知障碍; 脑或心肌中风; 脱髓鞘疾病，包括多发性硬化症，格林 - 巴利综合征和Charcot-Marie-Tooth疾病; 神经退行性疾病，包括帕金森病，Lou Gehrig氏病，亨廷顿舞蹈病和HIV痴呆; 神经外伤; 糖尿病，肥胖症，代谢综合征和喂养障碍; 实体瘤和白血病/淋巴瘤; 疼痛; 神经病变; 睡眠障碍和调节; 神经保护; 和炎症。

    TARGETS FOR DEPRESSION AND BIPOLAR DISORDERS
    4.
    发明申请
    TARGETS FOR DEPRESSION AND BIPOLAR DISORDERS 审中-公开
    遏制和双重障碍的目标

    公开(公告)号：WO2007106685A3

    公开(公告)日：2008-01-10

    申请号：PCT/US2007063447

    申请日：2007-03-07

    Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  SCRIPPS RESEARCH INST ,  BARTFAI TAMAS ,  HOYER DANIEL ,  BILBE GRAEME ,  CONTI BRUNO ,  MAIER RAINER ,  LU XIAOYING ,  SANNA PIETRO P ,  BARR ALASDAIR ,  MORALE MARIA CONCETTA

    Inventor： BARTFAI TAMAS ,  HOYER DANIEL ,  BILBE GRAEME ,  CONTI BRUNO ,  MAIER RAINER ,  LU XIAOYING ,  SANNA PIETRO P ,  BARR ALASDAIR ,  MORALE MARIA CONCETTA

    IPC: C12Q1/68 ,  A61P25/24

    CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

    Abstract: The expression patterns of biomarker genes reflect potential common underlying mechanisms for fast and slow acting antidepressant modalities. Biomarker genes were identified by examining the transcriptional changes in seven different brain regions of the rat brain induced by three clinically-effective antidepressant treatments: electro convulsive therapy (ECT), sleep deprivation (SD), and fluoxetine (FLX), the most commonly used slow onset antidepressant. The transcripts concomitantly regulated by several antidepressant treatments identified in the present invention, are therefore useful as biomarkers of medical conditions of the nervous system, e.g., but not limited to, depression (i.e., MD) and bipolar disorder, and are targets for fast onset, long duration antidepressants.

    Abstract translation: 生物标记基因的表达模式反映了快速和缓慢作用的抗抑郁药物模式的潜在共同潜在机制。 通过检查由三种临床有效的抗抑郁药物治疗引起的大鼠脑的七个不同脑区域的转录变化来鉴定生物标记基因：电惊厥治疗（ECT），睡眠剥夺（SD）和氟西汀（FLX），最常用的 缓慢的抗抑郁药。 因此，通过本发明中鉴定的几种抗抑郁药治疗伴随调节的转录物因此可用作神经系统的医学状况的生物标志物，例如但不限于抑郁（即MD）和双相性精神障碍，并且是快速发作的靶标 ，长期抗抑郁药。

    A NEW PERTUSSIS TOXIN DERIVED POLYPEPTIDE AND APPLICATIONS THEREOF
    6.
    发明申请
    A NEW PERTUSSIS TOXIN DERIVED POLYPEPTIDE AND APPLICATIONS THEREOF 审中-公开
    一种全新的毒素衍生的多肽及其应用

    公开(公告)号：WO1988004665A1

    公开(公告)日：1988-06-30

    申请号：PCT/SE1987000619

    申请日：1987-12-21

    Applicant: TRION FORSKNING- OCH UTVECKLINGS AKTIEBOLAG ,  BARTFAI, Tamas

    Inventor： TRION FORSKNING- OCH UTVECKLINGS AKTIEBOLAG

    IPC: C07K07/08

    CPC classification number: C07K14/235 ,  A61K39/00 ,  A61K49/00

    Abstract: A polypeptide of the formula H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr-Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y, in which X1 and X2 each represents an optional coupling-facilitating amino acid residue, and Y represents -OH or -NH2, and an artificial compound in free or carrier-associated form with the capability of binding to glyco-conjugates, especially immunoglobulins, which compound is chosen from the group consisting of said peptide and functional analogues and functional derivatives thereof. Additionally, there is described an artificial pertussis toxin antigen, which mainly consists of at least one peptide sequence reacting with antibodies induced by the native pertussis toxin selected from the above polypeptide and parts thereof. The above described artificial pertussis toxin antigen is included as a diagnostic antigen in a diagnostic immunoassay kit for the determination of antibodies induced by the native pertussis toxin in a sample of biological fluid, and as an immunizing component in a vaccine composition against whooping cough, respectively. Furthermore there is described an intradermal skin test composition comprising the above described artificial pertussis toxin antigen.

    NEW PEPTIDES AND APPLICATIONS THEREOF
    8.
    发明申请
    NEW PEPTIDES AND APPLICATIONS THEREOF 审中-公开
    新的肽及其应用

    公开(公告)号：WO1988002754A1

    公开(公告)日：1988-04-21

    申请号：PCT/SE1987000476

    申请日：1987-10-19

    Applicant: TRION FORSKNING- OCH UTVECKLINGS AKTIEBOLAG ,  BARTFAI Tamas

    Inventor： TRION FORSKNING- OCH UTVECKLINGS AKTIEBOLAG

    IPC: C07K07/08

    CPC classification number: C07K14/235 ,  A61K39/00 ,  Y10S530/825

    Abstract: The following new polypeptides are described: (a) H-X1-Asp-Asp-Pro-Pro-Ala-Thr-Val-Tyr-Arg-Tyr-Asp-Ser-Arg-Pro-Pro-Glu-Asp-X2-Y, (b) H-X1-Ser-Glu-Tyr-Leu-Ala-His-Arg-Arg-Ile-Pro-Pro-Glu-Asn-Ile-Arg-Arg-Val-Thr-Arg-Val-X2-Y, (c) H-X1-Ala-Phe-Val-Ser-Thr-Ser-Ser-Ser-Arg-Arg-Tyr-Thr-Glu-Val-Tyr-X2-Y, (d) H-X1-Gly-Ile-Thr-Gly-Glu-Thr-Thr-Thr-Thr-Glu-Tyr-Ser-Asn-Ala-Arg-Tyr-Val-X2-Y, and (e) H-X1-Leu-Glu-His-Arg-Met-Gln-Glu-Ala-Val-Glu-Ala-Glu-Arg-Ala-Gly-Arg-Gly-Thr-Gly-His-Phe-Ile-X2-Y, in which X1 and X2 each represents an optional coupling-facilitating amino acid residue, and Y represents -OH or -NH2. Additionally, there is described an artificial pertussis toxin antigen, which mainly consists of at least one peptide sequence reacting with antibodies induced by the native pertussis toxin selected from the above polypeptides (a) to (e) and parts thereof. The above described artificial pertussis toxin antigen is included as a diagnostic antigen in a diagnostic immunoassay kit for the determination of antibodies induced by the native pertussis toxin in a sample of biological fluid, and as an immunizing component in a vaccine composition against whooping cough, respectively. Furthermore there is described an intradermal skin test composition comprising the above described artificial pertussis toxin antigen.

Patent Agency Ranking